Roth Capital Has Pessimistic Outlook of CELZ FY2027 Earnings

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) – Roth Capital dropped their FY2027 EPS estimates for shares of Creative Medical Technology in a report released on Friday, March 21st. Roth Capital analyst J. Aschoff now expects that the company will post earnings of $3.00 per share for the year, down from their prior forecast of $3.26. The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.19) per share.

Creative Medical Technology Trading Down 16.7 %

Shares of NASDAQ:CELZ opened at $2.20 on Monday. The firm’s 50 day moving average is $3.77 and its two-hundred day moving average is $3.25. The firm has a market capitalization of $3.85 million, a P/E ratio of -0.58 and a beta of 1.70. Creative Medical Technology has a 52 week low of $1.96 and a 52 week high of $6.90.

Institutional Trading of Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Geode Capital Management LLC purchased a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned approximately 0.59% of Creative Medical Technology as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 1.42% of the company’s stock.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.